



14P3 Rec'd PCT/PTO 16 DEC 2005
PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

International Patent Application of

ASHTON et al.

Atty. Ref.: 620-401

Serial No. 10/556,901

Group: unknown

Filed: November 15, 2005

Examiner: Unknown

For: GLYOXALASE INHIBITORS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 16, 2005

Sir:

INFORMATION DISCLOSURE STATEMENT

- ☒ 1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits]
N/C
- ☐ 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
N/C
- ☐ 2.(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)]
\$180.00
- ☐ 3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment]
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

- ☒ 4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

- ☒ 5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
- ☐ 6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- ☐ a) The required Statement made in item 8 below; or
- ☐ b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
- ☐ 7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- ☐ a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- ☐ b) The required Statement is stated in item 8 below.
- ☐ 8. Statement under 37 CFR 1.97(e)
- ☐ a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- ☐ b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

- ☒ 9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.

By: _____



B.J. Sadoff
Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100


**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

620-401

10/556,901

APPLICANT

ASHTON et al.

(Use several sheets if necessary)

FILING DATE

GROUP

November 15, 2005

unknown

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/N.C./	4,898,870	02/1990	Narutomi et al			

FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
/N.C./	WO 99/35128	07/1999	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

/N.C./	Beilstein BRN: 5300594, 5139287, 5137246 & Shestopalov et al, J. Org. Chem. USSR, 1984, 1818-1827
✓	Beilstein BRN: 5133758 & Rodinovskaya et al, J. Org. Chem. USSR, Vol. 21, No. 11, 1985, 2230-2235
✓	Beilstein BRN: 4489731 & Rodinovskaya et al, Chem. Heterocycl. Compounds (Engl. Transl.), 1988, 658-664
✓	Beilstein BRN: 2047546 & Hudgins et al, Biochem. Pharmacol., Vol. 52, No. 8, 1996, 1227-1233
✓	Beilstein BRN: 7543266 & Gribble et al, J. Med. Chem., Vol. 39, No. 18, 1996, 3569-3584
✓	Beilstein BRN: 1994106, 246624 & Child et al, Arzneim Forsch, Vol. 30, No. 4a, 1980, 695-702
✓	Beilstein BRN: 3593422 & Chenard et al, J. Med. Chem., Vol. 33, No. 3, 1990, 1077-1083
✓	Beilstein BRN: 2334448 & Lohse et al, J. Agric. Food Chem., Vol. 48, No. 12, 2000, 5913-5923
✓	Thornalley et al, Crit. Rev. Oncol. Hematol., Vol. 20, 1995, 99-128
✓	Sakamoto et al, Clin. Cancer Res., Vol. 7, 2001, 2513-2518
	Davidson et al, The Journal of Urology, Vol. 161, 1999, 690-691
	Samadi et al, Urology, Vol 57, 2001, 183-187
	Ranganathan et al, Biochemica et Biophysic Acta, Vol 1182, 1993, 311-316
	Sakamoto et al, Blood, Vol. 95, 2000, 3214-3218
	Rulli et al, Breast Canc. Res. Treat, Vol 66, 2001, 67-72
	Thornalley et al, Gen. Pharmacol., Vol 27, No. 4, 1996, 565-573
	Johansson et al, Mol. Pharmacol., Vol. 57, 2000, 619-624
	Thornalley et al, J. Med. Chem., Vol. 39, 1996, 3409-3411
✓	Kalsi et al, J. Med. Chem., vol. 43, No. 21, 2000, 3981-3986
/N.C./	Sharkey et al, Cancer Chemother. Pharmacol., Vol. 46, 2000, 156-166

*Examiner: Nizal Chandrakumar/

Date Considered

01/15/2009

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)



INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

SERIAL NO.

620-401

10/556,901

APPLICANT

ASHTON et al.

FILING DATE

GROUP

November 15, 2005

unknown

U.S. PATENT DOCUMENTS

*EXAMINER
INITIAL

DOCUMENT NUMBER

DATE _____

NAME _____

CLASS

SUBCLASS

FILING DATE
IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT

DATE _____

COUNTRY

CLAS:

SUBCLASS

TRANSLATION

YES

NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Thornalley et al, Biochem. Pharmacol., Vol. 51, 1996, 1365-1372

Berge et al. J. Pharm. Sci., Vol. 66, No. 1, 1977, 1-19

Manna et al. Bioorg. & Med. Chem. Lett., Vol. 10, 2000, 1883-1885

Salman, Pharmazie, Vol. 54, 1999, 178-183

Racker, J. Biol. Chem., vol. 190, 1951, 685-696

Principato et al. Biochem. International, Vol. 6, No. 2, 1983, 249-255

N.C./Ridderstorm et al, Biochem. J., Vol. 314, 1996, 463-467

*Examiner

/Nizal Chandrakumar/

Date Considered

~~01/15/2009~~

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)